Enrollment to Start Later This Year in MONARCH Trial Testing STK-001 for Dravet
Stoke Therapeutics plans to begin enrollment later this year of Dravet syndrome patients for part A of its Phase 1/2a MONARCH trial to evaluate the investigational therapeutic STK-001, according to a press release. Most people with Dravet syndrome have mutations in one of the two copies (one…